All AbMole products are for research use only, cannot be used for human consumption.
Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is also a ferroptosis activator.
Proc Natl Acad Sci U S A. 2024 Apr 30;121(18).
Liver cancer development driven by the AP-1/c-Jun˜Fra-2 dimer through c-Myc
Sorafenib (BAY 43-9006) purchased from AbMole
Cell Death Dis. 2020 Oct 23;11(10):902.
The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma
Sorafenib (BAY 43-9006) purchased from AbMole
J Virol. 2020 Feb 14;94(5):e01791-19.
Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use
Sorafenib (BAY 43-9006) purchased from AbMole
Phytomedicine. 2015 Dec 1;1139-49.
Polyphyllin I induced-apoptosis is enhanced by inhibition of autophagy in human hepatocellular carcinoma cells.
Sorafenib (BAY 43-9006) purchased from AbMole
 |
Source | Phytomedicine (2015). Figure 1. Sorafenib was purchased from AbMole (Shanghai, China) |
| Method | Cell viability was determined by MTT assay | |
| Cell Lines | HCC HepG2 | |
| Concentrations | 0~100 µM | |
| Incubation Time | 24, 48, 72 hours | |
| Results | PPI dose- and time-dependently inhibited the proliferation of HepG2 cells, with IC50 values of 1.047 ± 0.376µM within 24 h. Sorafenib was used as a positive control in HepG2 cells. |
| Cell Experiment | |
|---|---|
| Cell lines | PLC/PRF/5, Hep3B, HepG2, HuH7 |
| Preparation method | PLC/PRF/5, Hep3B, HepG2 and HuH7 Cells were seeded in 96-well plates (3,000 cells/well) and incubated overnight for attachment, and were then treated with indicated agents in 10% FBS supplemented medium for 72 hours. The medium was replaced with MTT (0.5 mg/ml) at 37°C for 2 hours. After removal of medium, the cells were lysed with 200 μl per well dimethyl sulfoxide (DMSO), and absorbance at 570 nm was measured and the values of 50% inhibition concentration (IC50) for each drug were determined. |
| Concentrations | 0, 0.25, 0.5,1, 2 µM |
| Incubation time | 72 hours |
| Animal Experiment | |
|---|---|
| Animal models | PLC/PRF/5 xenograft model in female athymic nude mice of 4–5 weeks of age |
| Formulation | Dissolved in Cremophor EL/ethanol (50:50; Sigma Cremophor EL, 95% ethanol) at 4 × concentration. |
| Dosages | 60 mg/kg |
| Administration | Po, qd |
| Molecular Weight | 464.82 |
| Formula | C21H16ClF3N4O3 |
| CAS Number | 284461-73-0 |
| Solubility (25°C) | DMSO 45 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[3] Xin Chen, et al. Nat Rev Clin Oncol. Broadening horizons: the role of ferroptosis in cancer
| Related Raf Products |
|---|
| Sorafenib-d3
Sorafenib-d3 (Donafenib) is a deuterium-labeled Sorafenib, it is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. |
| XL-281
XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. |
| B-Raf IN 2
B-Raf IN 2 is a potent and selective BRAF inhibitor. |
| Brimarafenibum
Brimarafenibum (Brimarafenib) is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor, wtih antineoplastic effect. |
| Belvarafenib TFA
Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
